CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.53 billion. The enterprise value is $2.30 billion.
| Market Cap | 1.53B |
| Enterprise Value | 2.30B |
Important Dates
The last earnings date was Wednesday, October 28, 2026, after market close.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CONMED has 29.80 million shares outstanding. The number of shares has decreased by -2.14% in one year.
| Current Share Class | 29.80M |
| Shares Outstanding | 29.80M |
| Shares Change (YoY) | -2.14% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.91% |
| Owned by Institutions (%) | 112.59% |
| Float | 29.50M |
Valuation Ratios
The trailing PE ratio is 21.39 and the forward PE ratio is 11.13. CONMED's PEG ratio is 2.18.
| PE Ratio | 21.39 |
| Forward PE | 11.13 |
| PS Ratio | 1.12 |
| Forward PS | 1.09 |
| PB Ratio | 1.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.57 |
| P/OCF Ratio | 10.49 |
| PEG Ratio | 2.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.71, with an EV/FCF ratio of 17.35.
| EV / Earnings | 31.36 |
| EV / Sales | 1.68 |
| EV / EBITDA | 10.71 |
| EV / EBIT | 16.42 |
| EV / FCF | 17.35 |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.49 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 3.61 |
| Debt / FCF | 6.15 |
| Interest Coverage | 3.80 |
Financial Efficiency
Return on equity (ROE) is 7.10% and return on invested capital (ROIC) is 5.35%.
| Return on Equity (ROE) | 7.10% |
| Return on Assets (ROA) | 3.79% |
| Return on Invested Capital (ROIC) | 5.35% |
| Return on Capital Employed (ROCE) | 7.60% |
| Weighted Average Cost of Capital (WACC) | 7.09% |
| Revenue Per Employee | $351,099 |
| Profits Per Employee | $18,829 |
| Employee Count | 3,900 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, CONMED has paid $31.53 million in taxes.
| Income Tax | 31.53M |
| Effective Tax Rate | 30.04% |
Stock Price Statistics
The stock price has increased by +15.89% in the last 52 weeks. The beta is 0.89, so CONMED's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +15.89% |
| 50-Day Moving Average | 47.02 |
| 200-Day Moving Average | 41.62 |
| Relative Strength Index (RSI) | 60.84 |
| Average Volume (20 Days) | 444,241 |
Short Selling Information
The latest short interest is 846,967, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.84% |
| Short % of Float | 2.87% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
In the last 12 months, CONMED had revenue of $1.37 billion and earned $73.43 million in profits. Earnings per share was $2.41.
| Revenue | 1.37B |
| Gross Profit | 750.24M |
| Operating Income | 140.25M |
| Pretax Income | 104.96M |
| Net Income | 73.43M |
| EBITDA | 214.97M |
| EBIT | 140.25M |
| Earnings Per Share (EPS) | $2.41 |
Balance Sheet
The company has $47.97 million in cash and $815.87 million in debt, with a net cash position of -$767.89 million or -$25.77 per share.
| Cash & Cash Equivalents | 47.97M |
| Total Debt | 815.87M |
| Net Cash | -767.89M |
| Net Cash Per Share | -$25.77 |
| Equity (Book Value) | 1.06B |
| Book Value Per Share | 35.49 |
| Working Capital | 223.08M |
Cash Flow
In the last 12 months, operating cash flow was $146.31 million and capital expenditures -$13.62 million, giving a free cash flow of $132.69 million.
| Operating Cash Flow | 146.31M |
| Capital Expenditures | -13.62M |
| Depreciation & Amortization | 74.72M |
| Net Borrowing | -32.80M |
| Free Cash Flow | 132.69M |
| FCF Per Share | $4.45 |
Margins
Gross margin is 54.79%, with operating and profit margins of 10.24% and 5.36%.
| Gross Margin | 54.79% |
| Operating Margin | 10.24% |
| Pretax Margin | 7.67% |
| Profit Margin | 5.36% |
| EBITDA Margin | 15.70% |
| EBIT Margin | 10.24% |
| FCF Margin | 9.69% |
Dividends & Yields
CONMED does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.14% |
| Shareholder Yield | 2.14% |
| Earnings Yield | 4.68% |
| FCF Yield | 8.65% |
Analyst Forecast
The average price target for CONMED is $46.83, which is -9.07% lower than the current price. The consensus rating is "Hold".
| Price Target | $46.83 |
| Price Target Difference | -9.07% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 3.07% |
| EPS Growth Forecast (3Y) | 4.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 1.91 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 6 |